Myriad Genetics (MYGN) Current Deferred Revenue (2011 - 2022)

Myriad Genetics (MYGN) has 12 years of Current Deferred Revenue data on file, last reported at $200000.0 in Q3 2022.

• Current Deferred Revenue for Q3 2022 came in at $200000.0, down 98.26% year-over-year; the trailing twelve-month figure through Sep 2022 was $200000.0 (down 98.26% YoY), and the FY2021 annual result was $5.2 million, down 84.1% from the prior year.
• Current Deferred Revenue declined to $200000.0 in Q3 2022 per MYGN's latest filing, from $300000.0 in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $32.8 million in Q2 2020 and troughed at $200000.0 in Q3 2022.
• A 5-year average of $10.2 million and a median of $2.6 million in 2018 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2020 and 2022: Current Deferred Revenue soared 1438.1% in 2020, then slumped 98.67% in 2022.
• A 5-year view of Current Deferred Revenue shows it stood at $2.4 million in 2018, then soared by 50.0% to $3.6 million in 2019, then soared by 808.33% to $32.7 million in 2020, then slumped by 84.1% to $5.2 million in 2021, then plunged by 96.15% to $200000.0 in 2022.
• Business Quant data shows MYGN's Current Deferred Revenue at $200000.0 in Q3 2022, $300000.0 in Q2 2022, and $700000.0 in Q1 2022.